Kailera Therapeutics grants stock options to officer
Kailera Therapeutics reported that officer Paul D. Burgess received two grants of stock options, each covering 100,000 shares of common stock at an exercise price of $16.00 per share.
Rhea-AI Filing Summary
Kailera Therapeutics reported that officer Paul D. Burgess received two grants of stock options, each covering 100,000 shares of common stock at an exercise price of $16.00 per share. These are compensation awards, not open‑market purchases.
One option grant vests over time, with 25% vesting on April 16, 2027 and the remainder in 36 equal monthly installments, subject to continued service. The second grant vests only if the company’s stock price reaches $40 during a defined performance period or in a qualifying change in control, with both awards expiring on April 16, 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 200,000 shares
Grant/Award
2 txns
Insider
Burgess Paul D.
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 100,000 | $0.00 | $0.00 |
| Grant/Award | Stock Option (right to buy) | 100,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 200,000 contracts (Direct)
Footnotes (2)
- F1. The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.
- F2. The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.
Key Figures
Time-based option grant size: 100,000 options
Performance-based option grant size: 100,000 options
Exercise price: $16.00 per share
+4 more
7 metrics
Time-based option grant size
100,000 options
Stock Option (right to buy) award to Paul D. Burgess
Performance-based option grant size
100,000 options
Stock Option (right to buy) award with price hurdle
Exercise price
$16.00 per share
Exercise price for both stock option grants
Time-based vesting start
April 16, 2027
25% of time-based options vest on this date
Performance vesting stock price
$40 per share
Stock price required for performance options to vest
Performance Measurement Period
Oct 16, 2026–Apr 16, 2030
Window to meet $40 stock price condition
Option expiration
April 16, 2036
Expiration date for both option grants
Key Terms
Stock Option (right to buy), Performance Measurement Period, change in control transaction, vesting date, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Performance Measurement Period financial
"during the Performance Measurement Period, equals or exceeds $40 per share"
change in control transaction financial
"or (ii) the stock price in a change in control transaction"
vesting date financial
"subject to the Reporting Person's continued service through such vesting date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Kailera Therapeutics (KLRA) disclose about Paul D. Burgess’s new options?
Kailera Therapeutics disclosed that officer Paul D. Burgess received two grants of stock options, each for 100,000 shares at a $16.00 exercise price, as equity compensation rather than open-market purchases, with time-based and performance-based vesting conditions attached.
What are the vesting terms for Paul D. Burgess’s time-based stock options at KLRA?
The time-based options vest 25% on April 16, 2027, then in 36 substantially equal monthly installments. Vesting is conditioned on Burgess’s continued service through each vesting date, so the award delivers value gradually over more than four years if employment continues.
How do the performance-based options for Paul D. Burgess at Kailera Therapeutics vest?
The performance-based options vest only if Kailera’s average daily closing price on Nasdaq or a change-in-control transaction price reaches at least $40 during the October 16, 2026 to April 16, 2030 Performance Measurement Period, subject to Burgess’s continued service through that vesting date.
What is the exercise price and expiration date of the KLRA options granted to Burgess?
Both option grants to Paul D. Burgess have a $16.00 per share exercise price and expire on April 16, 2036. This means he can buy shares at $16.00 if the options vest and are exercised before that expiration date, subject to the vesting conditions.
Are Paul D. Burgess’s new KLRA option grants open-market stock purchases?
No, the transactions are classified as grants or awards, not open-market purchases. They were issued as stock options with a $16.00 exercise price and specific vesting terms, meaning Burgess gains the right to buy shares later rather than buying common stock directly in the market.
What is the Performance Measurement Period mentioned in the KLRA option grant?
The Performance Measurement Period runs from October 16, 2026 through April 16, 2030. During this window, the company’s average daily closing price or a change-in-control transaction price must reach at least $40 for the performance-based options to vest, assuming continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
